A single drug brought Insmed nearly three times the revenue the entire company produced in the comparable three months a year earlier. BRINSUPRI generated $308.6 million in US commercial sales after its August 2025 approval, helping push total revenue from $107.4 million to $425.5 million.
That is the obvious read of the three months ended June 30: the launch has moved Insmed from a development-stage biotech toward a commercial business. Operating loss shrank from $312.9 million to $1.5 million, and net loss narrowed to $13.2 million from $321.7 million.
The less obvious part is the accompanying balance-sheet changes. Cash fell from $1.3 billion to $544.8 million, while accounts receivable rose from $55.0 million to $215.3 million. Sales arrived at scale; cash fell while accounts receivable rose.
Management attributes the revenue increase to the new product and a smaller contribution from ARIKAYCE. The company said:
"This increase was a result of $308.6 million of US commercial sales of BRINSUPRI following approval in August 2025 and an $8.9 million growth in sales of ARIKAYCE, primarily driven by growth in international sales."
Insmed, Form 10-Q, Aug. 6, 2026
The numbers make BRINSUPRI the center of gravity. ARIKAYCE added growth, but the new launch supplied most of the increase, turning a $107.4 million business into a $425.5 million one in a year.
The cash explanation covers six months rather than the three-month income statement, so the periods should not be blended. Still, it identifies the spending attached to the commercial ramp:
"The net cash used in operating activities during the six months ended June 30, 2026 and 2025 was primarily driven by commercial, clinical, and manufacturing activities related to ARIKAYCE, commercial and commercial readiness activities for BRINSUPRI, as well as other SG&A expenses, and clinical trial expenses related to brensocatib and TPIP."
Insmed, Form 10-Q, Aug. 6, 2026
That list is the filing’s operating reality in plain English: the commercial ramp involved commercial, manufacturing, research, and headcount-related costs. Research and development rose 18.5% to $210.0 million, while diluted shares increased 14.8% to 217.4 million. The company is selling a product, but it is also funding the organization and pipeline needed to sell and develop more of them.
The cash balance also includes a specific AstraZeneca item. Insmed disclosed AstraZeneca as a partner in 22 filings, and said the latest cash decline included a $15.0 million milestone payment after European Commission approval of BRINSUPRI, partly offset by stock-option exercise proceeds. That payment is a discrete event, not a general explanation for the operating cost base, but it shows how approval milestones can move cash as the product expands.
The latest close was $98.79, little changed on Aug. 5. The more consequential unresolved detail is in working capital: accounts receivable grew almost fourfold year over year alongside the commercial sales increase. Insmed’s next quarterly report will put the commercial sales number beside the cash and receivables balances again, leaving one question: what cash balance and accounts receivable balance will the company report alongside BRINSUPRI sales?
Insmed’s 10-Q leaves the next report to answer what cash and accounts receivable will accompany BRINSUPRI’s commercial sales.